Literature DB >> 31474589

Feasibility of sentinel lymph node mapping of the ovary: a systematic review.

Federica Dell'Orto1, Pim Laven2, Martina Delle Marchette1, Sandrina Lambrechts3, Roy Kruitwagen2, Alessandro Buda4.   

Abstract

Pelvic and para-aortic lymphadenectomy is routinely performed in early ovarian cancer to define the stage of the disease. However, it may be associated with increased blood loss, operative time, and length of hospitalization. The sentinel lymph node technique has been shown to be safe and feasible in vulvar, uterine, and cervical cancer. Data detailing feasibility and outcomes of sentinel lymph node mapping in ovarian cancer are scarce.To summarize the studies evaluating the feasibility of sentinel lymph node detection from the ovary, examining the technique and detection rate.A systematic search of the literature was performed using PubMed and Embase from June 1991 to February 2019. Studies describing the sentinel lymph node technique and lymphatic drainage of the ovaries were incorporated in this review. Ten articles were selected, comprising a total of 145 patients. A variety of agents were used, but the primary markers were technetium-99m radiocolloid (Tc-99m), patent blue, or indocyanine green, and the most common injection site was the ovarian ligaments.The overall sentinel lymph node detection rate was 90.3%.We propose a standardized technique sentinel lymph node mapping in ovarian cancer, using indocyanine green, or Tc-99m and blue dye as alternative tracers, injected in both the suspensory and the infundibulopelvic ligament of the ovary. © IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ovarian cancer; sentinel lymph node

Mesh:

Substances:

Year:  2019        PMID: 31474589     DOI: 10.1136/ijgc-2019-000606

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial.

Authors:  Victor Lago; Pilar Bello; Beatriz Montero; Luis Matute; Pablo Padilla-Iserte; Susana Lopez; Tiermes Marina; Marc Agudelo; Santiago Domingo
Journal:  Int J Gynecol Cancer       Date:  2020-05-23       Impact factor: 3.437

Review 2.  [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes].

Authors:  Anne Kathrin Höhn; Christine E Brambs; Ramona Erber; Grit Gesine Ruth Hiller; Doris Mayr; Dietmar Schmidt; Elisa Schmoeckel; Lars-Christian Horn
Journal:  Pathologe       Date:  2021-05       Impact factor: 1.011

3.  Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice.

Authors:  P Laven; J J Beltman; J E Bense; M A van der Aa; T Van Gorp; M C Vos; D Boll; Hgj Arts; N Reesink; J B Trimbos; Rfpm Kruitwagen
Journal:  Surg Open Sci       Date:  2021-10-14

4.  Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Authors:  Pim Laven; Roy Kruitwagen; Petra Zusterzeel; Brigitte Slangen; Toon van Gorp; Jochem van der Pol; Sandrina Lambrechts
Journal:  J Ovarian Res       Date:  2021-10-13       Impact factor: 4.234

5.  Editorial: Future Perspectives of Sentinel Node Mapping in Gynecological Oncology.

Authors:  Angela Santoro; Frediano Inzani; Giuseppe Angelico; Fabio Martinelli; Andrea Papadia; Gian Franco Zannoni
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

Review 6.  Sentinel Lymph Node Mapping: Current Applications and Future Perspectives in Gynecology Malignant Tumors.

Authors:  Tianyou Wang; Yan Xu; Wenyu Shao; Chao Wang
Journal:  Front Med (Lausanne)       Date:  2022-06-29

7.  Utility of Intraoperative Fluorescence Imaging in Gynecologic Surgery: Systematic Review and Consensus Statement.

Authors:  Ignacio Zapardiel; Julio Alvarez; Manel Barahona; Pere Barri; Ana Boldo; Pera Bresco; Isabel Gasca; Ibon Jaunarena; Ali Kucukmetin; Gloria Mancebo; Borja Otero; Fernando Roldan; Ramón Rovira; Enma Suarez; Alvaro Tejerizo; Anna Torrent; Mikel Gorostidi
Journal:  Ann Surg Oncol       Date:  2020-10-23       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.